Free Trial

enGene (ENGN) Competitors

enGene logo
$3.70 +0.01 (+0.27%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$3.70 +0.00 (+0.14%)
As of 07/25/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ENGN vs. KALV, OCS, ANAB, AVBP, VIR, IOVA, AMLX, SION, CRMD, and TNGX

Should you be buying enGene stock or one of its competitors? The main competitors of enGene include KalVista Pharmaceuticals (KALV), Oculis (OCS), AnaptysBio (ANAB), ArriVent BioPharma (AVBP), Vir Biotechnology (VIR), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), Sionna Therapeutics (SION), CorMedix (CRMD), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.

enGene vs. Its Competitors

KalVista Pharmaceuticals (NASDAQ:KALV) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

KalVista Pharmaceuticals currently has a consensus price target of $26.29, indicating a potential upside of 80.29%. enGene has a consensus price target of $23.29, indicating a potential upside of 529.34%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than KalVista Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KalVista Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
enGene
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

64.2% of enGene shares are owned by institutional investors. 10.5% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 10.4% of enGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

enGene's return on equity of -32.60% beat KalVista Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
KalVista PharmaceuticalsN/A -134.07% -82.65%
enGene N/A -32.60%-28.26%

KalVista Pharmaceuticals has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.42, suggesting that its share price is 142% less volatile than the S&P 500.

KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KalVista PharmaceuticalsN/AN/A-$183.44M-$3.69-3.95
enGeneN/AN/A-$55.14M-$1.65-2.24

In the previous week, enGene had 1 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 8 mentions for enGene and 7 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.68 beat enGene's score of -0.30 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
KalVista Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
enGene
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
3 Very Negative mention(s)
Neutral

Summary

enGene beats KalVista Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENGN vs. The Competition

MetricenGeneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$188.58M$3.05B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.00%
P/E Ratio-2.2421.3228.3920.08
Price / SalesN/A280.80430.0899.95
Price / CashN/A42.7636.2258.56
Price / Book0.698.378.675.88
Net Income-$55.14M-$55.19M$3.25B$258.89M
7 Day Performance-2.37%5.86%4.30%3.70%
1 Month Performance3.06%17.29%10.57%11.71%
1 Year Performance-58.89%4.39%35.68%17.98%

enGene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENGN
enGene
2.8244 of 5 stars
$3.70
+0.3%
$23.29
+529.3%
-58.9%$188.58MN/A-2.2431
KALV
KalVista Pharmaceuticals
3.9579 of 5 stars
$15.56
+1.1%
$26.29
+68.9%
+1.3%$768.79MN/A-4.22100
OCS
Oculis
2.2461 of 5 stars
$17.50
flat
$35.33
+101.9%
+54.7%$764.09M$780K-6.632
ANAB
AnaptysBio
1.8926 of 5 stars
$26.17
+1.0%
$42.38
+61.9%
-27.6%$761.53M$111.87M-5.40100News Coverage
Positive News
Analyst Forecast
AVBP
ArriVent BioPharma
2.1419 of 5 stars
$21.55
-2.3%
$39.29
+82.3%
+0.2%$754.39MN/A-5.7240Analyst Forecast
Analyst Revision
VIR
Vir Biotechnology
3.5237 of 5 stars
$5.52
+2.0%
$30.25
+448.0%
-47.0%$747.87M$74.21M-1.31580News Coverage
IOVA
Iovance Biotherapeutics
4.6218 of 5 stars
$2.49
+11.7%
$12.22
+390.9%
-66.8%$744.67M$212.68M-2.01500Analyst Forecast
Options Volume
Gap Up
High Trading Volume
AMLX
Amylyx Pharmaceuticals
3.1408 of 5 stars
$8.21
-1.6%
$11.75
+43.1%
+324.5%$743.44M$87.37M-2.64200
SION
Sionna Therapeutics
N/A$17.44
+4.2%
$38.50
+120.8%
N/A$738.64MN/A0.0035Positive News
CRMD
CorMedix
2.7788 of 5 stars
$10.94
+0.7%
$17.14
+56.7%
+143.9%$736.58M$43.47M49.7330
TNGX
Tango Therapeutics
1.895 of 5 stars
$6.77
flat
$10.50
+55.1%
-30.8%$733.83M$42.07M-5.5590Positive News

Related Companies and Tools


This page (NASDAQ:ENGN) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners